Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-01-18 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于深圳华大基因股份有限公司开展外汇套期保值业务的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from CITIC Securities regarding Shenzhen BGI Genomics Co., Ltd.'s plan to conduct foreign exchange hedging business. It includes descriptions of the transaction purpose, methods, amounts, risk analysis, internal controls, and approvals by the board, independent directors, and supervisory board. The document is a formal verification and opinion report related to a specific financial transaction and risk management activity, not a full financial report, earnings release, or regulatory filing. It is not an announcement of a report publication but a substantive verification opinion. This fits the category of Audit Report / Information (AR), as it involves audit-like verification and opinions on a specific financial business activity, including compliance with regulations and internal controls. FY 2023
2023-01-18 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2023年度日常关联交易预计的核查意见
Management Reports Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2023 anticipated daily related-party transactions of Shenzhen BGI Genomics Co., Ltd. It includes extensive financial data on related-party transactions, approval procedures, and actual transaction amounts for 2022 and projections for 2023. The document references regulatory rules and internal governance related to related-party transactions, with detailed tables and explanations. It is not a brief announcement or a certification letter but a substantive report containing financial data and management explanations about related-party transactions. This fits the category of a Management Report (MDA), which covers management's detailed explanation of financial results, business trends, and outlook, especially regarding related-party transactions and their impact on the company.
2023-01-18 Chinese
关于使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the investment types, amounts, risk analysis, board and supervisory approvals, and compliance with regulatory requirements. The document does not contain financial statements or detailed financial results but rather informs shareholders and the market about the company's plan and approval to use idle raised funds for cash management purposes. This fits the category of a Capital/Financing Update (CAP) as it relates to the management and use of raised capital funds, specifically the temporary investment of idle raised funds. The document length is about 5540 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the appropriate classification is CAP with high confidence.
2023-01-18 Chinese
关于使用暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding the use of temporarily idle own funds for cash management. It details the investment purpose, types, amounts, risk analysis, control measures, and approvals by the board and supervisory committee. The document is a formal disclosure about the company's financing activity related to cash management, including investment in financial products with idle funds. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, audit report, or management report. It is not a report publication announcement since it contains substantive information about the financing activity itself. The document fits best under Capital/Financing Update (CAP) as it updates on the company's use of capital and financing activities involving idle funds management.
2023-01-18 Chinese
关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2023 first extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures, registration details, and agenda items. It does not contain financial statements or results but is a formal announcement to shareholders about the meeting and how to participate. The document length is about 4541 characters, which is relatively short and focused on meeting logistics and voting instructions. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. It is not an Annual Report, Earnings Release, or other financial report. Therefore, the correct classification is PSI with high confidence.
2023-01-18 Chinese
第三届监事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen BGI Genomics Co., Ltd. It details the meeting date, attendance, agenda items, and voting results on various company matters such as related party transactions, cash management, foreign exchange hedging, and liquidation of a subsidiary. The document does not contain financial statements or detailed financial analysis but rather formal meeting resolutions and decisions. It is not an annual or interim report, audit report, or earnings release. It is not a call transcript or investor presentation. It is a formal announcement of board-level decisions, specifically from the Supervisory Board, which falls under the category of Board/Management Information (MANG). The document length is under 5,000 characters and contains detailed meeting resolutions, not just a brief announcement or a certification, so it is not RPA or RNS. Therefore, the best classification is MANG with high confidence.
2023-01-18 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.